Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?

Ann Oncol. 2024 May;35(5):409-411. doi: 10.1016/j.annonc.2024.03.003. Epub 2024 Mar 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant / methods
  • Female
  • Humans
  • Immunotherapy / methods
  • Neoadjuvant Therapy* / methods
  • Neoplasm, Residual* / pathology
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / pathology
  • Triple Negative Breast Neoplasms* / therapy